A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa
- 30 April 2009
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 60 (4), 565-573
- https://doi.org/10.1016/j.jaad.2008.11.898
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativaBritish Journal of Dermatology, 2007
- Infliximab for the Treatment of Hidradenitis SuppurativaDermatology, 2007
- Quality of life impairment in hidradenitis suppurativa: A study of 61 casesJournal of the American Academy of Dermatology, 2007
- Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patientsJournal of the American Academy of Dermatology, 2007
- Adalimubab in the management of hidradenitis suppurativaJournal of the American Academy of Dermatology, 2007
- Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumabJournal of the American Academy of Dermatology, 2006
- Etanercept: effective in the management of hidradenitis suppurativaBritish Journal of Dermatology, 2006
- Medical treatment of hidradenitis suppurativaExpert Opinion on Pharmacotherapy, 2004
- The prevalence of hidradenitis suppurativa and its potential precursor lesionsJournal of the American Academy of Dermatology, 1996
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989